← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV26행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 1
Cytochrome P450 (CYP, Cytochrome P450, Cytochrome P450 (CYP) Cocktail)
Amgen·Metastatic Castration-resistant Pr…
174 trials
Overview
Program
Cytochrome P450 (CYP) Cocktail
Overview
Company
Amgen
Overview
Modality
ANTIBODY
Overview
Target
Metastatic Castration-resistant Prostate
Overview
Indication
Metastatic Castration-resistant Prostate Cancer; Prostate Cancer
Overview
Phase
PHASE_1
Overview
Status
DISCONTINUED
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
MoA
Mechanism
inhibits the expression of CYP2J2 by modulating the focal adhesion kinase/Src/extracellular signal-regulated kinase signaling pathway
MoA
Biomarker
biomarker in OSCC management
PK/PD
Species
Rat
PK/PD
Animal (cat.)
Rat, In vitro
PK/PD
Experiment
pharmacokinetic
Toxicology
Species
Rat
Toxicology
Animal (cat.)
Rat
Toxicology
Major finding
thrombocytopenia
Clinical
Safety signal
thrombocytopenia
Clinical
Selected reported efficacy
ORR 12.79%
Clinical
Reported ORR
12.79%
Clinical
Result source
ClinicalTrials.gov NCT05981365
Clinical
Program phase
PHASE_1
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT05981365